MX2022014586A - Métodos y composiciones para tratar la fuga vascular. - Google Patents

Métodos y composiciones para tratar la fuga vascular.

Info

Publication number
MX2022014586A
MX2022014586A MX2022014586A MX2022014586A MX2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A MX 2022014586 A MX2022014586 A MX 2022014586A
Authority
MX
Mexico
Prior art keywords
syndecan
compositions
methods
respiratory distress
distress syndrome
Prior art date
Application number
MX2022014586A
Other languages
English (en)
Inventor
Michael Simons
Federico Corti
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2022014586A publication Critical patent/MX2022014586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen anticuerpos anti-sindecano-2 y composiciones que comprenden dicho anticuerpo y métodos útiles para tratar el síndrome de dificultad respiratoria aguda, incluyendo el síndrome de dificultad respiratoria aguda inducido por la enfermedad de coronavirus 2019, en un sujeto en necesidad del mismo; el método comprende administrar al sujeto una cantidad efectiva para tratar el síndrome de dificultad respiratoria aguda de un agente disruptivo del sindecano-2; los agentes disruptivos del sindecano-2 pueden incluir por lo menos uno de los anticuerpos anti-sindecano-2 y/o por lo menos un péptido disruptivo del sindecano-2.
MX2022014586A 2020-05-22 2021-05-21 Métodos y composiciones para tratar la fuga vascular. MX2022014586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063029062P 2020-05-22 2020-05-22
PCT/US2021/033759 WO2021237159A1 (en) 2020-05-22 2021-05-21 Methods and compositions to treat vascular leak

Publications (1)

Publication Number Publication Date
MX2022014586A true MX2022014586A (es) 2023-05-17

Family

ID=78707631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014586A MX2022014586A (es) 2020-05-22 2021-05-21 Métodos y composiciones para tratar la fuga vascular.

Country Status (9)

Country Link
US (1) US20230203187A1 (es)
EP (1) EP4153207A4 (es)
JP (1) JP2023537452A (es)
KR (1) KR20230024289A (es)
CN (1) CN116437953A (es)
AU (1) AU2021273980A1 (es)
CA (1) CA3179428A1 (es)
MX (1) MX2022014586A (es)
WO (1) WO2021237159A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215787A1 (en) * 2022-05-04 2023-11-09 Vst Bio Corporation Compositions and methods for selective regulation of vascular permeability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150143625A (ko) * 2013-04-16 2015-12-23 오르브센 테라퓨틱스 리미티드 신데칸 2의 의학적 용도
WO2016154019A1 (en) * 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US10358497B2 (en) * 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
US20210113654A1 (en) * 2018-05-31 2021-04-22 Yale University Methods and Compositions to Alleviate Vascular Permeability

Also Published As

Publication number Publication date
US20230203187A1 (en) 2023-06-29
AU2021273980A1 (en) 2023-01-19
JP2023537452A (ja) 2023-09-01
KR20230024289A (ko) 2023-02-20
CN116437953A (zh) 2023-07-14
EP4153207A1 (en) 2023-03-29
EP4153207A4 (en) 2024-06-12
CA3179428A1 (en) 2021-11-25
WO2021237159A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
BR112022019085A2 (pt) Uso de agentes para tratamento de condições respiratórias
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
MX2007003795A (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
NO20070702L (no) Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2022014332A (es) Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo.
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.
JOP20220218A1 (ar) طريقة لعلاج الحالات المصاحبة لكوفيد 19
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021004603A (es) Dosificacion.
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability
WO2023019095A3 (en) Momelotinib combination therapy
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.